European Interbalkan Medical Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2005
NCT00758732
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

European Interbalkan Medical Center | Interbalkan Hospital | Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki | Spine Department and Deformities, Interbalkan European Medical Center, Thessaloniki, PC 55535, Greece | Spine Department and Deformities, Interbalkan European Medical Center, Thessaloniki, PC 55535, Greece; Department of Minimally Invasive and Endoscopic Spine Surgery, Athens Medical Center, Athens, PC 15124, Greece | Stylianos Kapetanakis

Active Ingredients

Drugs in Phase 3 Trials (1)

platelet-rich plasma (1 trial)

Drugs in Phase 2 Trials (4)

carboplatin (paraplatin) (2 trials)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5